



FORESIGHT
TRAINING
COURSE

VII

GIANNI BENZI
PHARMACOLOGICAL
RESEARCH FOUNDATION



The Gianni Benzi Pharmacological Research Foundation (FGB) is a registered not-for-profit scientific research organisation aimed at promoting research in innovative biological, medical and other products for human use. Besides research, the activities of the Foundation are addressed to high level educational initiatives that are mainly devoted at consolidating the existing knowledge and taking into account the current European strategies concerning Regulatory Sciences.

The Gianni Benzi Foundation yearly organises the 'Foresight Training Courses' (FTCs), that are short intensive courses devoted to create a critical mass of expertise in the different areas of Regulatory Sciences (medical devices, foods, medicinal products), with particular reference to the innovative advancement of the European Pharmaceutical and Biological

products sectors. Six Foresight Training Courses have been performed until today with participants from 21 EU/non EU Countries.

The experience of the Foresight Training Courses is mainly aimed at sharing the existing knowledge in the area and fostering the networking of experts from Universities, Industries, and national and EU Regulatory Agencies, all taking an active role in building the new scenario of Regulatory Sciences.

The FTCs also gain their strength from the involvement of experts, decision makers and all interested stakeholders (Regulators, Researchers, Health Professionals, Private and Public Companies, Patient Associations) coming from outside Europe, making them an interesting occasion of debate and a collaborative effort within the existing international networks.



The VII Foresight Training Course will be held in the context of the European Projects Forum “Nex-t-work”.

Nex-t-work represents the right scenario to organise the seventh edition of the Foresight Training Course and the ideal context to share its objectives and its mission with all the stakeholders involved in the evolution of Regulatory Sciences and Human Research.

Nex-t-work is aimed at networking and developing international relations with the various players of the EU grant-funded projects in order to share best practises

and stimulate the intersectoral collaboration between academic and educational Institutions, Universities, Companies, Public Authorities, Innovation Centres, Scientific Associations, Regulatory Experts, Research Networks, Investors, Students and Patients.

Furthermore, the inclusion of the VII Foresight Training Course in the wider scenario of Nex-t-work, in which workshops and training initiatives are scheduled, will offer our guests the possibility to participate in different sessions of their interest, complementary and open to different targets.

You are kindly invited to participate in these initiatives that will be held in Castellana Marina (Taranto - Italy), October 2-4 2014. It will include the following sessions:

1. Project-best practises sessions: DEEP, DEferiprone Evaluation in Paediatrics and InNerMeD-I-Network, two EC-funded projects for Rare Diseases in which the Foundation is involved, will be presented;
2. Training sessions: aimed to launch three International Masters promoted by the Community of Mediterranean Universities (CMU) and the Ondokuz Mayıs University (OMU), Turkey, in collaboration with the Gianni

Benzi Foundation. The first two Masters are devoted to health and nutrition (‘Health, Food Safety and related Policies for the Mediterranean Area - HEFSA’ Master and the ‘International Master in Regulatory Sciences’ - IMRS), while the third one is focused on ‘Tourism and Culture in the Mediterranean Area’ - EMCT;

3. International Conference: Mediterranean, European policies and the new framework 2020 (organised by Nex-t-work);
4. Focus session: progresses and opportunities in conducting Paediatric will be discussed at the presence of relevant European and non-European scientists (organised by CVBF - Consorzio per Valutazioni Biologiche e Farmacologiche and TEDDY - European Network of Excellence for Paediatric Clinical Research);
5. Project session: dedicated to present the results of the ‘RiMedRi’ Network for regenerative medicine aimed at integrating clinical-biological biobanks in the South of Italy (Sicily);
6. Foresight “Health, Biotechnology and ICT”: some relevant novelties in the European Regulatory framework will be discussed and will involve different stakeholders. The session will focus on the European Reference Networks (ERNs) and Biomarkers and Good Genomics Practices (GGP) in the medicines developmental process. Companies’ success stories will be presented.

Looking forward to seeing you.

The President

Professor Adriana Ceci

InNerMed-I-Network

InNerMeD-I-Network is a European project funded by the Executive Agency for Health & Consumers (DG SANCO) under the Second Programme to be the first European Information Network on Inherited NeuroMetabolic Diseases (iNMDs). It started on the 1st of April 2013.

InNerMeD-I-network wants to create a multimedial network of information targeted on diagnosis and treatment of iNMDs and based on the collection and exchange of validated information among scientific communities, health professionals, patients associations and all interested stakeholders.

iNMDs are a group of rare genetic metabolic diseases that impact on the brain causing mental retardation and progressive neurodegeneration which, if not promptly treated, could end in early death.

The project aims to increase current knowledge on iNMDs and speed up the timely and precise identification of patients who may benefit of the available treatments (experimental and marketed). The network will also favour biomedical research, straightening research capacities and fostering innovative therapeutic tools derived from the recent scientific advancements.



Chair: F. Carnevale

- InNerMeD-I-Network: The first European Network on Inherited NeuroMetabolic Diseases (**F. Bonifazi**)
- ICT Platform to store and disseminate iNMDs information (**V. Giannuzzi**)
- Networking and widespread of scientific contents to reduce the knowledge gap (**C. Bellettato**)
- Neurometabolic congenital disease: performing diagnosis and clinical follow up in an Italian Paediatric Hospital (**R. Fischetto**)
- New insights molecular diagnostic tests (**M. Carella**)

Chairs and Speakers:

Cinzia Bellettato

Scientific officer and medical writer at Brains for Brain Foundation - Italy

Fedele Bonifazi

InNerMeD Project Manager and vice President of the Gianni Benzi Pharmacological Research Foundation - Italy

Massimo Carella

Laboratory of Medical Genetics, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo - Italy

Francesco Carnevale

Past Head of Neurometabolic Genetic Diseases Department, Paediatric Hospital Giovanni XXIII - Italy

Rita Fischetto

U.O.C. Metabolic Diseases, Paediatric Hospital Giovanni XXIII - Italy

Viviana Giannuzzi

Scientific Coordinator of the Gianni Benzi Pharmacological Research Foundation - Italy

Deep

The main goal of the DEEP project is the development of a new formulation of deferiprone for the treatment of iron overload in paediatric patients affected by congenital, transfusion-dependent anaemias such as β -thalassaemia major, also known as “Mediterranean anaemia”, and sickle cell disease (SCD).

Congenital haemoglobinopathies are the commonest congenital rare diseases in the world. Mediterranean population are specifically affected with a variable trend depending on immigration movements and fluxes. Patients survival and quality of life depend on regular red blood cells transfusions and the use of iron chelators to reduce the iron overload.

Deferiprone is the first oral iron chelator approved in Europe and in other Mediterranean countries. After its market authorisation, many advantages have been reported in patients affected by thalassaemia and other haemoglobinopathies because of better compliance and increased effect at cardiac level, dealing to lowered mortality.

The DEEP project has been designed specifically for children, starting from the youngest and including adolescents. It is aimed to better define the safety, the tolerability and the efficacy of this drug in order to make its anticipated therapeutic benefits available to the entire paediatric population. Thus, the primary objectives of the DEEP Project are:

a) To perform pharmacokinetics, efficacy and safety studies of deferiprone in children in order to provide data to be included in an updated SmPC. (DEEP 1)

b) To provide a new formulation specifically tested for young children. The new formulation has a different strength (80 mg/ml) from what is currently marketed (Ferriprox 100 mg/ml) and has improved the flavour in order to increase its acceptance (and consequently compliance) by young children. (DEEP 2)

c) To provide long term safety data on all the current uses (including combination with Deferoxamine) in a large perspective/retrospective population. (DEEP 3)

The decision of the European Commission to fund this plan of research is compliant with the recent European Regulation on Paediatric Medicines that requests that all medicines with a potential benefit to children should be appropriately studied in this population. On November 11th, 2011 the clinical development described in the project, received a positive opinion by the Paediatric Committee (PDCO) at the European Medicines Agency (EMA).

Noticeably the project involves 16 Partners from 6 EU countries and 4 non EU, all representing the main affected geographic area by congenital haemoglobinopathies. Apulia is strongly involved in this disease and the Policlinic of Bari is performing a key-role in terms of management and clinical activities, in particular acting as the Coordinating Centre of the DEEP-1 Clinical Trial and hosting the Drug Management Service for all the Italian recruiting centres.

3:00 pm

Agenda

Thursday, October 2nd 2014

Chairs: P. Giordano - C. De Lorenzo

- Best practices in paediatric clinical research: the DEEP experience (**D. Bonifazi**)
- Participating in an international research network: the experience of the Policlinic of Bari (**V. Dattoli**)
- Results from the PK/PD clinical trial and patients' recruitment for the efficacy/safety and long-term safety studies (**G. C. Del Vecchio**)
- Responsibilities of the Hospital Pharmacy of the Policlinic of Bari: innovative roles and tasks (**M. Lattarulo**)

Joint discussion on paediatric rare diseases with patients' associations

Ludovico Abbaticchio

Board of Directors Italian Medicines Agency - Italy

Adriana Ceci

DEEP Project Scientific Coordinator - Italy

Gaetano Lodeserto

Vice President of Associazione per la Guarigione della Talassemia di Manduria - Italy

Giuseppe Mele

Managing Board Federazione Nazionale dei Talassemici e Drepanocitici - Italy

Chairs and Speakers:

Donato Bonifazi

Managing Director of the Consorzio per Valutazioni Biologiche e Farmacologiche, DEEP Project Manager - Italy

Vitangelo Dattoli

General Director of Polyclinic of Bari - Italy

Ciro De Lorenzo

President of Associazione Talassemici Taranto - Italy

Giovanni Carlo Del Vecchio

DEEP1 - PK/PD Clinical Trial Coordinating Investigator - Italy

Paola Giordano

Associate Professor of Paediatrics, Aldo Moro University of Bari - Italy

Michele Lattarulo

Director of the Hospital Pharmacy of the Polyclinic of Bari - Italy

Promoted by Community of Mediterranean Universities, Ondokuz Mayıs University (Turkey), Gianni Benzi Pharmacological Research Foundation

The workshop aims to enhance the ongoing internationalisation processes for the development of high level educational activities, based on the networking experience, carried out successfully by the Community of Mediterranean Universities (CMU) and the Gianni Benzi Pharmacological Research Foundation (FGB).

Three international Masters (Euromediterranean Master in Cultures and Tourism; Health, Food Safety and related Policies for the Mediterranean Area Master and the International Master in Regulatory Sciences) that the Community of Mediterranean Universities and the Ondokuz Mayıs University (OMU) are organising in collaboration with the Gianni Benzi Foundation, will be officially presented and discussed in the presence of representatives of Institutions, Universities and companies working in these fields.

EMCT. The EMCT Master's Degree (**Euromediterranean Master in Cultures and Tourism**) aims to provide students with the necessary knowledge to take decisions related to the management of tourism and culture and heritage activities in the Mediterranean area. Its goal is to overcome boundaries and differences, as well as build mutual understanding among Euro-Mediterranean countries; to create an academic partnership of higher education and research institutions by developing a network of specialised study programmes among Euro-Mediterranean universities.

HEFSA. The use of Healthy and Safe Food is aimed to protect humans from food related diseases and incorrect lifestyles. Thus, the availability of environmentally sustainable and properly preserved food is necessary. The objective of the Master in “**Health, Food Safety and related Policies for the Mediterranean Area**” is to train professionals in the agricultural and medical-biological sectors, able to act at any level, including Public Health Institutions, to promote correct agricultural, social-health, food and nutrition strategies and policies even providing opinion on how to comply with current regulations.

IMRS. In light of the very fast evolving of science and technology, the process of translating biological and biomedical discoveries into new therapies and products for human use, has become increasingly complex and requires that the ‘Regulatory Sciences’ keep up timely and effectively the advances in biomedical science and technology. The **International Master in Regulatory Sciences** aims to create and to update highly experienced professionals in the field of Regulatory Sciences, to provide them full and update knowledge at European/non-European level.

Session 1: Internationalisation of high level education - the CMU experience and mission

Chairs: **C. Di Benedetto** - **Y. Kesim**

- The cooperation in high level education among the Mediterranean Universities (**F. Losurdo**)
- Internationalisation Experience in Euromediterranean Area: Presentation of Euromediterranean Master in Cultures and Tourism - EMCT (**N. Kiziltan**)
- The role of high level training in Health and Food Safety. Presentation of HEFSA International Master (**C. Di Benedetto**)

Discussion



Session 2: High level education for Health and Biotechnology - the FGB experience and mission

Chairs: **V. Silano** - **L. Trabace**

- The role of high level training in Regulatory Sciences (**A. Ceci**)
- Presentation of the International Master in Regulatory Sciences (**M. Lupo**)
- The Industry's expectations and needs:
 - EUCOPE (**O. Sude**)
 - Genovax (**D. Criscuolo**)
- The Academy's expectations and needs (**A. Altavilla**)
- The Regulatory Agencies's expectations and needs (**L. Abbaticchio**)



RIMEDRI - Rete Integrata clinico-biologica di biobanche per la MEDicina RIgenerativa

The project “Rete Integrata Clinico-Biologica di Biobanche per la Medicina Rigenerativa” (Integrated Clinical-Biological Biobanks Network for Regenerative Medicine- RIMedRi) aimed at creating a regional network of certified and accredited biobanks for therapeutic and research purposes. The project fits in a scenario characterised by the fragmentation of research and the lack of common standards for biobanks, which results in a duplication of similar projects, waste of energy and resources and difficulty of developing a policy of long-term loans. In such a scenario, the RIMedRi project has launched a process

aimed at creating a regional network of biobanks operating in synergy, with high levels of quality and with the enormous potential of being able to enter as a regional hub in the context of a more extensive biobank networks at both national and European level. This project is implemented through a process of data integration and harmonization of methodologies, which results in an enhancement of the scientific value of biospecimen collections in the Sicilian Region, without neglecting the potential for future extension of this network, both at national and international level.



9:30 am

Agenda

Friday, October 3rd 2014

Chair: **D. Bonifazi - A. Ceci**

- Integrated Clinical-Biological Biobanks Network for Regenerative Medicine - RIMedRi (**A. Maggio**)
- The certification path and the RIMedRi Network quality management system (**V. Lomonaco**)
- The spontaneous collection of biological samples, Biological Resources Centres and biobanks (**F. Caristi**)
- Key aspects of biobanks regulation (**L. Ruggieri**)
- The RIMedRi platform for the collection and the dissemination of information linked to the biological material (**A. Caprera**)

Chairs and Speakers:

Donato Bonifazi

Responsible for networking, development and sustainability of the RIMedRi project - Italy

Adriana Ceci

President of the Gianni Benzi Pharmacological Research Foundation - Italy

Andrea Caprera

RIMedRi Bioinformatician on behalf of Parco Tecnologico Padano Foundation – Italy

Francesca Caristi

RIMedRi Researcher on behalf of National Biological Resource Centre - Italy

Virna Lomonaco

RIMedRi project operational coordinator on behalf of National Biological Resource Centre - Italy

Aurelio Maggio

RIMedRi project Scientific Coordinator and Head of Haematology and Blood and haematopoietics organs rare diseases Department, Azienda Ospedaliera Ospedali Riuniti “Villa Sofia-Cervello” - Italy

Lucia Ruggieri

Researcher at Italian Group for Pharmacoeconomics Studies - Italy

International Conference

The **Europe 2020 strategy** aims to boost the EU economy over the next decade in order to become smart, sustainable and supportive. These three priorities are mutually reinforcing and aim to help the EU and the Member States to achieve high levels of employment, productivity and a more social cohesion.

In particular, the European Union has set five ambitious objectives, to be reached by 2020, in the field of **employment, innovation, education, social inclusion and climate/energy**.

The international conference on “Mediterranean, European policies and the new framework 2020” is aimed at discussing the main challenges that the Italian Presidency is already facing as well as the Mediterranean as a place of cooperation and a new model of economic and social development to which all are called to participate.



- the Europe 2020 Strategy, to better understand how to effectively achieve the primacy of small and medium industries, that have always been the backbone of the European economy as well as the policies to improve industrial competitiveness;
- actions in favour of unemployment, with particular reference to the youth, through mobility, that has to be fostered through social dialogue, creation of new jobs, structural reform of labour market and the investment in human capital;
- the creation of new jobs and a new entrepreneurs class based on new technologies and the developments of the digital communication;
- new employment opportunities in the agricultural sector through investments in agro-industrial, tourism, catering and initiatives to protect the countryside;
- how to promote tourism and culture, through projects and policies aimed to enhance the cultural and territorial heritage;
- policies for research and innovation that are the pillars to develop a sustainable growth and are today more and more strictly connected with improvement of health, services for elderly people and biotechnologies.

TEDDY is an European Paediatric Network funded under the EC-FP6 Program in 2005 as an Excellence Research Network aimed at developing paediatric medicines research and innovative studies. After expiring the funded period, TEDDY has consolidated its activities in the field through a research Consortium Agreement among 41 partners from 14 countries, coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF), that is also involved in the GRiP Project as CVBF-TEDDY.

Despite the incentives following the entry into force of the Paediatric Regulation in 2007, in Europe there is still a serious lack of drugs tailored for children (especially for newborns). Considering the challenges posed by performing paediatric studies, qualified experts and institutions must join the efforts to develop

safety and efficacy profile of drugs for children and to develop age-appropriate dosages and formulations. For this reason, the networking action performed by TEDDY and other paediatric experiences is strongly recommended to share information and best-practices on a global basis in paediatrics.

This meeting is proposed as the first General Assembly after the agreement has been signed and will be the occasion for the nomination of the scientific bodies of the network. It will include an update on the relevant innovative initiatives of interest for the paediatric research in Europe and a posters session directly promoted by the researchers participating in the network.

Chairs and Speakers (1/2):

Paola Baiardi

GRiP Project WP Leader Work Package 4
“New Methods for Clinical Studies in Paediatrics” - Italy

Donato Bonifazi

Managing Director of Consorzio per Valutazioni Biologiche e Farmacologiche - Italy

Sebastian Botzenhardt

CloSed Project, University Hospital Erlangen - Germany

Adriana Ceci

Former Coordinator of the Network of Excellence TEDDY, President of the Gianni Benzi Pharmacological Research Foundation - Italy

Carlo Giaquinto

GRiP Coordinator, President of Fondazione Penta - Italy

Ilse Grosch-Woerner

Charite Universitätsmedizin - Germany

2:30 pm

Agenda

Friday, October 3rd 2014

Chairs: D. Bonifazi - I. Grosch-Woerner

- TEDDY experience in developing paediatric research in Europe and Horizon 2020 (**A. Ceci**)
- From TEDDY to CloSed - UKERs pathway in the framework of European Research Funding (**S. Botzenhardt**)
- Paediatric Clinical Trials in Albania: in the absence of a regulation, Big Pharma give way to research-driven EU funded projects: the safety-efficacy paediatric clinical trial in thalassaemia (**M. Kreka**)
- A Joint Degree in Paediatric Pharmacology and Clinical trials in children: an initiative of GRiP - the Global Research in Paediatrics Network of Excellence (**P. Rossi**)
- Promoting a cost-efficient strategy for people with Autism Spectrum Disorder (ASD) across Europe - PASDE: a new proposal under Horizon 2020 developed into the TEDDY Network (**A. Tarpan**)
- GRiP and EnprEMA, the European Networks for Paediatric Research (**C. Giaquinto**)
- Innovative studies designs to favour paediatric research (**P. Baiardi**)
- Paediatric studies to reduce the off-label use (**E. Spaans**)
- TEDDY infrastructure, database and SOPs for paediatric clinical trials (**C. Manfredi**)

*Posters (or short communications) session: TEDDY researchers sharing proposals and results (**L. Ruggieri**)*

5:30 pm

Appointment of TEDDY Network Scientific Committee and Scientific Coordinating Committee

Chairs and Speakers (2/2):

Manika Kreka

DEEP-2 Principal Investigator, Mother Teresa University Hospital - Albania

Cristina Manfredi

Consorzio per Valutazioni Biologiche e Farmacologiche - Italy

Paolo Rossi

Head of the Paediatric Department at the University Hospital Bambino Gesù - Italy

Lucia Ruggieri

Italian Group for Pharmacoeconomic Studies - Italy

Edwin Spaans

Erasmus MC Sophia Children's Hospital - the Netherlands

Adelaide Katherine Tarpan

Romanian Angel Appeal Foundation - Romania

High-level educational activities in the field of health and biotechnology are strongly requested to grant the ability in creating international, shared and successful research experiences to the professionals.

The Foresight Training Courses, yearly organised by the Gianni Benzi Pharmacological Research Foundation, are aimed to address the translation of innovative biological and biomedical discoveries into new therapies, products and care organisations, taking into account the complex system regulating these processes in Europe.

The Health and Biotechnology Foresight is focused on:


- The launch in Europe of a new interesting subject 'the European Reference Networks (ERNs)' aimed to identify and put together all the existing public care and research Institutions of excellence, in order to provide patients with the best available

treatments in European countries. This will be of particular interest in case of rare and very complex diseases;

- The increasing role of ICT in developing research and creating a more efficient, simplified and patients centred model for cure or experimental purposes;
- The use of genetic markers, derived by the biological science, as surrogate markers for developing drugs, to identify patient specific populations and to adapt treatment to single patient on a personalised basis scheme.

Successful stories of key research-based companies will be discussed in order to strengthen the interest and the collaboration among experts from universities, industries and public institutions.

The course will provide 4,7 Italian ECM credits for Healthcare Professionals.



Session 1: European Reference Networks (ERNs): 'A new vision for patients' health'

Chairs: R. Barbon Galluppi - A. Ceci

- ERN: Procedures, competences, skills in the European vision (**R. Cardone**)
- The European Reference Networks for Rare Diseases (**D. Taruscio**)
- Excellence to be translated in a new ERN
 - Paediatric issues (**M. Migdal**)
 - Rare haemoglobinopathies (**A. Maggio**)
- The role of ISCIII in fostering health research and innovation in Spain (**A. Beltrán García-Echániz**)

Session 2: New tools and innovation

Chairs: S. Cotecchia - G. Logroscino

- ICT role in Health (**G. Visaggio**)
- Concept paper on good genomics biomarker practices: how to prepare a guideline for researchers, industry and patients? (**E. Bosone**)
- Biotechnological approaches in plant breeding to reduce the impact of agrochemicals on human health (**L. Ricciardi**)

Session 3: Role and relevance of Biotechnology in a growing society

Chairs: G. Pesole - C. Altomare

- The H-BIO experience (**M. Svelto**)
- Successful Biotech initiatives:
 - Masmec (**P. Larizza**)
 - Dompè (**M. Allegretti**)
 - Serendipractice o DAISY-Net (**F. Losurdo**)
 - SER & Practices (**M. Morga**)
- Biomarkers clinical use: from laboratory to the product (**M. Papale**)
- The growing role of Patients in health research and cure (**R. Barbon Galluppi**)

Chairs and Speakers (1/2):

Marcello Allegretti

Chief Scientific Officer at Dompè SpA - Italy

Cosimo Damiano Altomare

Professor of Pharmaceutical Chemistry at the Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro' - Italy

Renza Barbon Galluppi

President of Uniamo Federazione Italiana Malattie Rare Onlus - Italy

Alfonso Beltrán García-Echániz

Deputy General Director Instituto de salud Carlos III - Spain

Enrico Bosone

Director of Regulatory Affairs and Compliance at Celgene, Board of Directors Representative at SIAR - Italy

Rosetta Cardone

Department Programmazione ed ordinamento del SSN, Direzione Generale della Programmazione Sanitaria, Ministry of Health - Italy

Adriana Ceci

President of the Gianni Benzi Pharmacological Research Foundation - Italy

Susanna Cotecchia

Professor of Pharmacology, Faculty of Biotechnology, University of Bari 'Aldo Moro' - Italy

Pietro Larizza

Director of MASMEC SpA - Italy

Giancarlo Logroscino

Department of Basic Medical Sciences, Neuroscience and sense organs, University of Bari 'Aldo Moro' - Italy

Francesco Losurdo

CEO of DAISY-Net Srl, General Secretary of Community of Mediterranean Universities - Italy

Chairs and Speakers (2/2):

Aurelio Maggio

Director of U.O.C Ematologia e malattie rare del sangue e degli organi ematopoietici, Ospedali Riuniti Villa Sofia-Cervello - Italy

Marek Migdal

Deputy Head, PICU, PDCO EMA member, Children's Memorial Health Institute - Poland

Massimiliano Morga

Operative Manager, SER & Practices Srl - Italy

Massimo Papale

Researcher at University of Foggia; scientific consultant at Bioxygen srl; scientific consultant at Apuliabiotech s.c.ar.l. - Italy

Graziano Pesole

Director of the Institute of Biomembranes and Bioenergetics, National Research Council of Bari - IBBE - CNR, Department of Biochemistry and Molecular Biology 'E. Quagliariello', University of Bari 'A. Moro' - Italy

Luigi Ricciardi

Community of Mediterranean Universities - CMU, University of Bari - Italy

Maria Svelto

President of the High Technology District H-Bio Puglia - Italy

Domenica Taruscio

Director of the Italian National Centre for Rare Diseases, Italian National Institute of Health - Italy

Giuseppe Visaggio

President of SER & Practices Srl, University of Bari - Italy

Course Location



The biggest Convention & Spa resort in Italy, a prestigious complex in the heart of Magna Grecia, NOVA YARDINIA. In the most striking landscape of the Ionian coast between Apulia and Basilicata, located a few steps from white shores and crystal clear sea, immersed between the Nature Reserve Aleppo secular pines in a perfect union of sea and nature, architecture and wellness, Nova Yardinia (Castellaneta Ma-

rina - Taranto) offers 4 and 5 star buildings, satisfying different holiday and self-contained accommodation demands. There is Free Internet WI-FI Connection in common areas and meeting centre. With its 3.500 square metres of environments dedicated to wellness, Nova Yardinia represents the biggest Thalasso SPA of Italy and the Mediterranean Sea.


Nova Yardinia Resort

Loc. Principessa - S.S. 106 km 466.600

74010 Castellaneta Marina (Ta)

Tel. +39 099 8204901 - +39 099 8204020

How to reach Nova Yardinia Resort



ACCOMODATION COSTS (under agreement)

1 day of full board:

Calanè Hotel **** - single room: 110 € per person

1 day of full board:

Calanè Hotel **** - double room: 90 € per person

accommodation at the Kalidria Hotel *****:

add 25 € per day

Lunch or dinner: 25 €

Drinks are included.

Thalasso Package (steam bath, turkish bath, water path):

entrance € 25 per day

Transfer from/to Bari/ Brindisi Airport one way:

€ 25 one way, min. 3 persons

All the costs are VAT included.

Distance from the airport of:

Bari - 90 km (60 min) / Brindisi - 100 km (60 min)

Distance from the railway station of:

Bari - 90 km (60 min) / Taranto - 45 km (30 min) / Castellaneta M. - 5 km (5 min)

Distance from the toll road:

Taranto A14 - 20 km (5 min)

[illegible]



GIANNI BENZI

**PHARMACOLOGICAL RESEARCH
FOUNDATION**

Via Abate Eustasio, 30 - 70010 Valenzano (BA) Italy

Tel. +39 080 467 04 30 - Fax +39 080 467 02 81

VAT Number 06780820723 - Tax Code 93347800729

info@benzifoundation.org - www.benzifoundation.org